- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
7
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
7 companies
Camurus
Market Cap: SEK 36.1b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 606.50
7D
-3.9%
1Y
-14.9%
Bonesupport Holding
Market Cap: SEK 15.0b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 228.20
7D
0.9%
1Y
-22.6%
BioArctic
Market Cap: SEK 28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 322.00
7D
-2.8%
1Y
16.5%
Genovis AB (publ.)
Market Cap: SEK 1.4b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 20.70
7D
5.6%
1Y
-18.7%
Egetis Therapeutics
Market Cap: SEK 3.7b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 8.00
7D
15.3%
1Y
54.7%
Isofol Medical
Market Cap: SEK 256.4m
Operates as a clinical stage biotech company.
ISOFOL
SEK 0.80
7D
-2.2%
1Y
-7.4%
Moberg Pharma
Market Cap: SEK 508.6m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 10.78
7D
-3.2%
1Y
32.9%